Investor Presentation Q1-Q3 2020

70 Investor presentation First nine months of 2020 Novo Nordisk is expanding into other serious chronic diseases Serious chronic diseases are often associated with diabetes and obesity New therapeutic areas represent patient populations with high unmet medical needs Estimated patients Number of related deaths 70% of people with diabetes die from atherosclerotic CVD CVD ~420 million ~20 million annually CVD 40% of people hospitalised for heart failure have diabetes Estimated patients Diagnosis rate • NASH 80% of people with NASH live with obesity and 35% have diabetes NASH ~15-40 million¹ ~20%2 CKD • 40% of people with diabetes have diabetic nephropathy and 50% have obesity CKD ~200 million -20% Novo Nordisk® 1 Internal forecast comprising the USA, Europe and Japan; 2 Diagnosis rate is considered a major uncertainty to the forecast CVD: Cardiovascular disease; NASH: Non-alcoholic Steatohepatitis; CKD: Chronic kidney disease Source: Source: Diabetes Care 2005 Jan; 28(1): 164-176; Abera SF et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015, 2017; Heart Disease and Stroke Statistics, American Heart Association, 2017; Williams CD et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy, 2011; Addressing the global burden of chronic kidney disease through clinical and translational research, 2014

View entire presentation